We hypothesized that the targeted inhibition of PRMT5 in NDRG2low ATL and solid cancer cells would specifically induce anti-cancer effects as synthetic lethality through the inhibition of cytoplasmic PRMT5/HSP90 activity. This evidence concerns the gene HSP90AA1 and cancer.